Suven Life gets 7 product patents

Highlights

Biopharmaceutical firm Suven Life Sciences on Wednesday said it received one product each from Europe, Hong Kong, Japan, Macau, the African Regional Intellectual Property Organisation (ARIPO) and South Korea for a drug used in the treatment of neuro-degenerative diseases.

Hyderabad: Biopharmaceutical firm Suven Life Sciences on Wednesday said it received one product each from Europe, Hong Kong, Japan, Macau, the African Regional Intellectual Property Organisation (ARIPO) and South Korea for a drug used in the treatment of neuro-degenerative diseases.

The patents, which are valid till 2031, are to their New Chemical Entities (NCEs) for CNS therapy.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally," said Venkat Jasti, CEO, Suven Life Sciences.

With these new patents, Suven has a total of 1 granted patent from ARIPO (African Regional Intellectual Property Organisation), 19 from Europe, 18 from Hong Kong, 18 from Japan, 7 from Macau and 18 from South Korea.

These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like phase-I or phase-II, the company said.

Show Full Article
Download The Hans India Android App or iOS App for the Latest update on your phone.
More Stories


Top